NASDAQ:DNLI
Denali Therapeutics Inc. Stock News
$16.16
+0.720 (+4.66%)
At Close: May 01, 2024
Is Denali Therapeutics (DNLI) A Smart Long-Term Investment?
02:04pm, Friday, 18'th Feb 2022 Insider Monkey
Baron Funds, an asset management firm, published its “Baron Growth Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Earnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to Decline
08:03pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Denali Receives Formal Letter Regarding FDA Hold On Alzheimer''s Potential Program
02:21pm, Monday, 14'th Feb 2022 Benzinga
As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI ) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND) application was placed on clinical hold. Denali has now received a formal clinical Full story available on Benzinga.com
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
01:29pm, Thursday, 10'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer
Merc
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
01:00pm, Thursday, 10'th Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that new longer-term data from an ongoing Phase 1/2 clinical trial of DNL310 (ETV:IDS) are being presented today at WORLD Symposium . DNL310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of MPS II (Hunter syndrome).
12 biotech stocks to consider buying now as prospects for the sector brighten this year
02:01pm, Monday, 07'th Feb 2022 MarketWatch
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.
12 biotech stocks to consider buying now as prospects for the sector brighten this year
04:53pm, Sunday, 06'th Feb 2022
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
01:22pm, Sunday, 06'th Feb 2022 Benzinga
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some bi
Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™
02:00pm, Tuesday, 01'st Feb 2022 Benzinga
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced upcoming presentations from the DNL310 (ETV:IDS) clinical development program to be given at the 18 th Annual WORLD Symposium ™, which will be held February 7-11, 2022, in San Diego, California, and virtually. DNL310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of MPS II (Hunter syndrome). An oral presentation will provide longer-term safety, biomarker (glycosaminoglycans and lysosomal lipids) and exploratory clinical data on Cohorts A and B from an ongoing Phase 1/2 clinical trial of DNL310 in MPS II. A poster presentation will provide details on a planned, potentially registrational Phase 2/3 clinical trial of DNL310 in MPS II.
Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight
01:00am, Tuesday, 18'th Jan 2022 Benzinga
Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.
Why Denali Therapeutics Stock Is Sinking This Week
10:18pm, Thursday, 13'th Jan 2022 The Motley Fool
The FDA placed a hold on the company's planned clinical trial of an experimental Alzheimer's disease drug.
Why Denali Therapeutics Stock Is Sinking This Week
05:18pm, Thursday, 13'th Jan 2022
The FDA placed a hold on the company's planned clinical trial of an experimental Alzheimer's disease drug.
G Medical, ChemoCentryx top healthcare gainers; Denali, Immix among losers
03:02pm, Thursday, 13'th Jan 2022 Seeking Alpha
G Medical Innovations (GMVD) +20%. ChemoCentryx (CCXI) +12%. Denali Therapeutics Inc. (DNLI) -13%. Immix Biopharma (IMMX) -11%.
Denali Therapeutics falls on clinical hold for Alzheimers candidate (NASDAQ:DNLI)
01:19pm, Thursday, 13'th Jan 2022 Seeking Alpha
Denali Therapeutics (DNLI) is trading ~13.9% lower in the pre-market after announcing a clinical hold imposed by the FDA for the companys experimental therapy for Alzheimers
Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application
01:00pm, Thursday, 13'th Jan 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to c